Pardoprunox

Pardoprunox
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name 7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one;
CAS Number	269718-84-5;
PubChem CID	6918524;
ChemSpider	5293721;
UNII	5R72CHP32S;
CompTox Dashboard (EPA)	DTXSID80949746 ;
ECHA InfoCard	100.206.783
Chemical and physical data
Formula	C12H15N3O2
Molar mass	233.271 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cl.O=C2Oc1c(cccc1N2)N3CCN(C)CC3;

Pardoprunox (INN; code name SLV-308) is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued.^[1]^[2]^[3] It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.^[1]

Quick Facts Clinical data, Routes ofadministration ...

Pardoprunox acts as a D₂ (pK_i = 8.1) and D₃ receptor (pK_i = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT_1A receptor (pK_i = 8.5) full agonist (IA = 100%).^[1]^[4] It also binds to D₄ (pK_i = 7.8), α₁-adrenergic (pK_i = 7.8), α₂-adrenergic (pK_i = 7.4), and 5-HT₇ receptors (pK_i = 7.2) with lower affinity.^[1]^[4] Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.^[4]^[5]

See also